Shares of Merck & Co., Inc. (NYSE:MRK) ended Thursday session in green amid volatile trading. The shares closed up +0.61 points or 0.99% at $61.94 with 9.21 million shares getting traded. Post opening the session at $61.90, the shares hit an intraday low of $61.69 and an intraday high of $62.41 and the price vacillated in this range throughout the day. The company has a market cap of $168.66 billion and the numbers of outstanding shares have been calculated to be 2.77 billion shares.
Merck & Co., Inc. (MRK) announced that it will host a teleconference for investors following the presentation of data at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 – 11. The call will take place on Sunday, Oct. 9 at 6:30 p.m. CEST (12:30 p.m. EDT). Company executives will provide an overview of data presented and address questions. Investors, journalists, and the general public may access a live audio webcast of the call on Merck’s website at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx. A replay will be available at www.merck.com.
Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 84673546. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 84673546. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team at the conclusion of the call.
Shares of Tokai Pharmaceuticals Inc (NASDAQ:TKAI) ended Thursday session in green amid volatile trading. The shares closed up +0.02 points or 1.49% at $1.36 with 1.27 million shares getting traded. Post opening the session at $1.36, the shares hit an intraday low of $1.24 and an intraday high of $1.44 and the price vacillated in this range throughout the day. The company has a market cap of $33.00 million and the numbers of outstanding shares have been calculated to be 22.63 million shares.
Tokai Pharmaceuticals Inc (TKAI) on September 8, 2016 announced that its Board of Directors has initiated a review of strategic alternatives for the company focused on maximizing stockholder value.
Potential strategic alternatives that may be explored or evaluated as part of this review include a sale of the company, a reverse merger, a business combination or a sale, license or other disposition of corporate assets of the company. There is no set timetable for this process and there can be no assurance that this process will result in any such transaction. In conjunction with this process, the company is continuing to assess the best path forward for its galeterone clinical trial program. The company now anticipates all patients enrolled in the ARMOR3-SV clinical trial will discontinue treatment by the end of the year.